Compugen Ltd.

CGEN Healthcare Biotechnology

Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.

2.08 0.08 +4.00%
Market cap
$187.6M
P/E
5.5×
Fwd P/E
−7.2×
Dividend yield
—
F-score
7/9
Altman Z
−0.37
Beneish M
−1.59
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
2 — — — — — 3 4 5 7
P/E ratio
0.00 — 0.00 — 0.00 0.00 0.00 0.00 0.00 4.14
P/S ratio
364.28 — 6.72 — 48.68 22.92 3.96 11.31 4.92 1.96
Altman Z-Score
14.57 — (4.47) — 27.57 4.19 (4.72) (2.81) (3.87) (0.37)
P/FCF ratio
0.00 — 0.00 — 0.00 0.00 0.00 0.00 2.16 1.41
Altman Z″-Score (non-manufacturers)
(1.40) — (16.25) — 1.74 (2.53) (8.19) (7.46) (8.87) (0.84)
P/Operating CF
(10.13) — (4.68) — (37.64) (14.14) (2.40) (6.84) 2.76 4.52
Beneish M-Score
(5.65) — — — — (1.69) (2.68) 5.58 (5.68) (1.59)
P/B ratio
4.08 — 3.22 — 8.05 3.39 0.79 2.67 2.49 1.39
Price to Tangible BV
4.08 — 3.22 — 8.05 3.39 0.79 2.67 2.49 1.39
EV/Sales
277.86 — 4.16 — 42.39 15.46 (1.44) 8.01 1.21 (0.04)
EV/EBITDA
0.00 — 0.00 — 0.00 0.00 0.52 0.00 0.00 0.00
EV/Operating CF
(3.72) — (1.11) — (9.97) (3.20) 0.24 (1.14) 0.53 (0.03)
EV/FCF
(3.32) — (1.10) — (10.00) (3.17) 0.24 (1.13) 0.53 (0.03)
Quick Ratio
13.22 5.03 4.66 6.60 12.27 7.21 7.23 4.36 5.26 6.56
Current Ratio
13.22 5.03 4.66 6.60 12.27 7.21 7.23 4.36 5.26 6.56
Net Debt/EBITDA
1.98 0.85 2.09 1.57 4.04 3.40 2.40 3.99 6.46 (4.65)
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.01 0.00 0.39 0.00 0.02 0.04 0.07 0.31 0.24 0.54
Operating CF/Net income
0.63 0.83 0.59 1.02 0.95 0.67 1.01 1.91 (3.49) 0.90
Capex/Depreciation
(1.75) (0.24) (0.11) 0.23 (0.17) (0.63) (0.99) (0.88) 0.11 30.50
ROE
(41.07%) (79.87%) (67.93%) (72.35%) (37.57%) (30.20%) (36.55%) (26.19%) (23.63%) 44.84%
ROA
(36.97%) (67.46%) (49.17%) (51.12%) (30.92%) (25.29%) (29.77%) (17.40%) (12.04%) 26.03%
ROIC
(1,022.31%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (55.97%) 0.00% 0.00%
Return on Tangible Assets
(49.30%) (125.09%) (56.55%) (67.47%) (24.69%) (31.73%) (44.49%) (20.95%) (16.42%) 28.02%
Average Days of Receivables
591.07 0.00 18.52 0.00 850.09 332.15 117.63 693.03 35.92 11.95
Research and Development Expense of Revenue
3,447.89% 0.00% 170.33% 0.00% 1,138.00% 478.23% 408.64% 103.03% 89.04% 31.28%
Selling, General and Administrative Expense of Revenue
1,197.05% 0.00% 54.35% 0.00% 533.80% 195.00% 150.01% 29.81% 35.94% 12.96%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
433.15% 0.00% 12.17% 0.00% 138.60% 71.27% 57.71% 10.61% 10.85% 2.59%
Graham Net Nets
0.21 — 0.26 — 0.11 0.27 1.13 0.34 0.34 0.66
Graham Number
0.00 — 0.00 — 0.00 0.00 0.00 0.00 0.00 3.03
Earnings Yield
(12.16%) — (18.34%) — (3.06%) (9.30%) (56.34%) (11.00%) (10.18%) 24.18%
Free Cash Flow Yield
(22.97%) — (56.50%) — (8.71%) (21.27%) (150.38%) (62.89%) 46.22% 71.14%
Revenue per Share
0.01 0.00 0.32 0.00 0.03 0.07 0.09 0.38 0.31 0.78
Operating CF per Share
(0.39) (0.60) (0.24) (0.44) (0.36) (0.27) (0.39) (0.41) 0.55 0.34
Capex per Share
(0.05) (0.01) 0.00 0.00 0.00 0.00 (0.01) 0.00 0.00 0.00
Free Cash Flow per Share
(0.44) (0.61) (0.24) (0.43) (0.36) (0.27) (0.40) (0.41) 0.55 0.34
Cash per Share
1.21 0.59 0.83 0.69 1.56 1.40 0.97 0.58 1.15 1.56
Shareholders Equity per Share
1.25 0.57 0.67 0.60 1.51 1.27 0.90 0.75 0.61 1.10
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
1.25 0.57 0.67 0.60 1.51 1.27 0.90 0.75 0.61 1.10
Free Cash Flow
(22.42) (31.04) (13.45) (27.66) (28.44) (23.04) (34.59) (36.06) 49.49 31.33
Working Capital
57.94 24.99 36.59 38.18 118.57 106.13 74.21 88.31 85.84 125.45
Capital Expenditures
(2.60) (0.38) (0.16) 0.23 (0.12) (0.29) (0.47) (0.17) (0.12) (0.30)
Net Current Asset Value
55.06 21.73 30.64 29.56 110.56 97.75 69.63 58.80 45.92 94.18
EV/EBIT
0.00 — 0.00 — 0.00 0.00 0.63 0.00 0.00 0.00
Capex to Sales
3.65 0.00 0.01 0.00 0.06 0.05 0.06 0.01 0.00 0.00
Price to Operating Income
0.00 — 0.00 — 0.00 0.00 0.00 0.00 0.00 4.56
Other line items
Depreciation/Fixed assets
0.25 0.34 0.41 0.42 0.42 0.28 0.31 0.16 (1.28) (0.01)
Cash ROIC
(17.93%) (51.97%) (16.22%) (33.65%) (11.65%) (10.26%) (21.43%) (30.92%) 31.29% 12.61%
Accounts Receivable Turnover
0.14 0.00 21.65 0.00 0.69 1.19 1.90 1.01 0.84 28.40
Accounts Payable Turnover
0.14 0.68 0.32 0.49 0.05 0.23 0.31 0.76 2.97 4.41
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
2,085.25 789.34 1,039.93 401.54 8,595.75 2,480.39 663.74 637.84 84.60 92.84
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
5.15 0.95 0.82 1.01 2.89 5.06 3.94 32.97 33.14 2.56
Average Payables
1.64 2.36 3.20 2.02 1.25 3.02 3.20 2.64 2.67 2.10
Average Assets
85.22 54.94 45.96 53.47 96.04 135.24 113.17 107.76 118.16 135.78
Average Common Equity
76.71 46.41 33.27 37.78 79.05 113.24 92.19 71.62 60.24 78.82

Fold the line items

Columns are period end dates